Eli Lilly and Company (LLY)
Is This Trend a Threat to Eli Lilly's Weight Loss Drug Dominance?
Eli Lilly's weight loss drugs have helped revenue and the stock price to soar in recent times. Demand is so high that Lilly and rival Novo Nordisk have ramped up manufacturing to try to address it.
Eli Lilly (LLY) Veteran Anat Ashkenazi to Join Alphabet as CFO
Eli Lilly and Company LLY announced that its executive vice president and chief financial officer (CFO) Anat Ashkenazi has resigned after serving for 23 years at the company. Ashkenazi has joined Google's parent company Alphabet GOOGL as CFO and senior vice president, effective Jul 31, 2024.
US FDA panel to vote on data, risk profile of Lilly Alzheimer's drug
A panel of outside experts to the U.S. health regulator will vote on Monday on whether data for Eli Lilly's experimental treatment, donanemab, shows it is effective for treating patients with early Alzheimer's disease.
Is It Possible Eli Lilly Is Breaking Out To New All-Time Highs?
Eli Lilly has been outperforming the S&P 500. The company's blockbuster drug Mounjaro has been approved in China, resulting in high demand and a strong earnings report. The five-year target price for Eli Lilly has been raised to $1,455 based on conservative earnings projections and a multiple of 40X.
Eli Lilly and Company (LLY) Lilly Oncology ASCO Investor Event (Transcript)
Eli Lilly and Company (NYSE:LLY ) Lilly Oncology ASCO Investor Event June 2, 2024 8:30 PM ET Company Participants Jake Van Naarden - Executive VP & President of Loxo Lillian Smyth - Senior Vice President and Global Development Head for Breast Cancer at Loxo John Pagel - Vice President and Head of Global Hematology at Loxo Geoff Oxnard - VP of Clinical Development, Global Head Thoracic Cancer at Loxo Arjun Balar - MD, Vice President, Global Clinical Development at Loxo Barry Taylor - Chief Scientific Officer of Loxo Kara Clinton - Senior Vice President Oncology Medical Affairs Winselow Tucker - Senior Vice President & Chief Commercial Officer for Loxo Conference Call Participants Evan Seigerman - BMO Capital Markets Seamus Fernandez - Guggenheim Securities Geoff Meacham - Bank of America Steve Scala - TD Cowen Chris Schott - JPMorgan Akash Tewari - Jefferies Dave Risinger - Leerink Partners Jake Van Naarden All right. Can everyone hear me, yes.
Britain considers offering Lilly weight-loss drug on better terms than Wegovy
Britain's medical costs regulator on Tuesday recommended Eli Lilly's weight-loss drug Mounjaro for some patients with obesity and suggested not placing a time limit on the medicine's use as it had for rival Novo Nordisk's Wegovy.
LLY Stock Today: How To Trade An Unbalanced Iron Condor That May Put $285 In Your Pocket
The profit zone ranges between 757.15 and 912.85.
Watch Out Wegovy: Here Comes Another Promising Anti-Obesity Candidate
One of Eli Lilly's anti-obesity candidates reported positive data in a phase 3 study. The results highlight the strong breadth of Lilly's portfolio in this promising area.
Prediction: These Could Be the Best-Performing Pharmaceutical Stocks Through 2030
Eli Lilly and Novo Nordisk are leaders in fast-growing therapeutic areas. Both companies have excellent track records of innovations and solid results.
Eli Lilly's Growth And Challenges: A Cautious Buy
Eli Lilly announced impressive Q1 2024 financial results, with revenue surging by 26% YoY and exceeding expectations for earnings per share. The company raised its full-year 2024 revenue guidance and adjusted earnings per share guidance. While facing challenges with the price of its stock and supply chain issues, Eli Lilly anticipates significant increases in shipment volumes in the second half of 2024.
This Is the Biggest Risk for Eli Lilly and Novo Nordisk Investors
Eli Lilly and Novo Nordisk have generated incredible returns for investors in the past few years. The surging popularity of their weight loss treatments has produced a lot of bullishness.
Aristocrats in Disguise: 3 Blue-Chip Stocks With Stealth Growth Potential
Although there is no hard-and-fast rule about what constitutes a blue-chip stock, they all tend to have certain qualities. They are large, financially stable companies that have been through numerous business and economic cycles that proved their worth in the end.
